PPARα serves as a new receptor of aspirin for neuroprotection.
Dhruv R PatelAvik RoyKalipada PahanPublished in: Journal of neuroscience research (2019)
Acetyl salicylic acid, commonly known as aspirin, has been being widely used as an anti-inflammatory drug for almost 100 years. However, there was no receptor known for this popular drug. Recently, we have established that peroxisome proliferator-activated receptor alpha (PPARα) acts as a novel receptor of aspirin. Activation of PPARα by aspirin stimulated a series of downstream signaling pathways that could potentially ameliorate different Alzheimer's disease (AD)-related pathologies. In this mini-review, we have discussed how aspirin-PPARα interaction plays a pivotal role in the amelioration of AD pathology via the stimulation of neurotrophic factors, upregulation of plasticity-associated genes, and removal of plaque burden in hippocampal neurons.
Keyphrases
- low dose
- cardiovascular events
- antiplatelet therapy
- insulin resistance
- signaling pathway
- coronary artery disease
- type diabetes
- cell proliferation
- anti inflammatory drugs
- fatty acid
- emergency department
- cardiovascular disease
- spinal cord
- genome wide
- percutaneous coronary intervention
- poor prognosis
- binding protein
- acute coronary syndrome
- brain injury
- transcription factor